Citations

Clear

3042 citation(s) found for "Kumar, S".

Menin regulates oncogenic cell identity transcriptional networks in multiple myeloma
Kumar, Subhasree , Franich, Rheana, Khong, Tiffany, Neville, Daniel, The, James, Rumler, Brandon, Alex, Shania, Dobbs, Grace, Lewis, Alexander C. , Hawkins, Edwin, Chesi, Marta, Spencer, Andrew, Gilan, Omer , Kats, Lev M. , Gruber, Emily , Franich, Rheana L. , Khong, Tiffany T. , Ang, Ching‐Seng , Rumler, Bradon, Howitt, George , Hawkins, Edwin, Bergsagel, P. Leif , Chesi, Marta , Spencer, Andrew

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.17.733047 Get It

Abstract Multiple myeloma (MM) is a heterogenous cancer that remains mostly incurable. A unifying feature of MM cells is a highly interconnected network of transcription factors and co-factors that coordinate the activity of super-enhancers to enforce myeloma cell identity. Targeting this network offers a promising avenue for therapeutic intervention across genetically diverse myeloma sub-types. Using integrated molecular and functional genomic approaches we identified Menin as a key driver of oncogenic gene expression in MM cells. Menin and its co-factor KMT2A bind at super-enhancers and maintain expression of essential myeloma genes, including IRF4. We demonstrate that Menin inhibitors, which have recently been approved for treatment of acute myeloid leukaemia, are highly active in myeloma cell lines and in vivo models. Combining Menin inhibitors with other super-enhancer targeting therapies such EP300/CREBBP inhibitors or immunomodulatory drugs (IMiDs) overcomes epigenetic plasticity in cells resistant to single agent treatment.
AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia
Crystal, R G, Weinsaft, Jonathan W. , Kaminsky, S B, Caragiulo, Anthony, Savage, Niamh, Patel, A, Gavrilova, Ralitza H. , Perlman, Susan , Galbraith, Madeline, Kahlon, Udhay, Krishnan, UM, Sanders, Abraham, Vo, Mary, Sarva, Harini, Yoo, Andrea, Sondhi, Dolan , De, Bishnu P., Mezey, Jason G. , Khan, Aashir, Selvan, Nithya, Bhalla, N P, Adler, Eric, Zesiewicz, Theresa, Caragiulo, Anthony , Patel, Aarti , Kaner, Robert J. , Yoo, Andrea S. , Aubert, Grégory , Selvan, Nithya, Bhalla, Naman Kumar

Mayo Clinic

JAMA Cardiology | June 17, 2026 | Volume: 11 | Issue: 8 | Pages: 709

10.1001/jamacardio.2026.1699 | PMID 42307907 Get It

Importance Friedreich ataxia (FA), a fatal, autosomal recessive disorder caused by pathogenic variants in the frataxin ( FXN ) gene, is characterized by progressive neurologic and cardiac disease, with cardiac disease being the major cause of death. Preclinical studies have demonstrated that systemic administration of AAVrh.10hFXN, an rh.10 serotype cardiotropic adenoassociated virus (AAV) vector expressing the normal human FXN coding sequence, reverses the cardiomyopathy in FXN-deficient mice. Objective To assess the safety and preliminary efficacy of administration of AAVrh.10hFXN to adults with FA cardiomyopathy. Design, Setting, and Participants This nonrandomized clinical trial evaluates the pooled data of 2 independent, open-label, dose-escalation trials that used the same gene therapy vector and similar clinical protocols among patients with FA cardiomyopathy at academic medical centers. Data were collected from February 22, 2022, to October 4, 2025, for trial 1 and from February 14, 2023, to September 10, 2025, for trial 2 and analyzed together from November 5, 2025, to March 12, 2026. Intervention AAVrh.10hFXN, administered intravenously in 3 dose cohorts (1.8 × 10 11 , 5.6 × 10 11 , and 1.2 × 10 12 vector genomes per kilogram of body weight). Main Outcomes and Measures In addition to safety as the primary outcome, multiple parameters of exploratory end points were assessed, including cardiac biopsy levels of FXN protein, cardiac magnetic resonance imaging–derived left ventricular mass index (LVMI), and serum high-sensitivity (hs) troponin I. Results Seventeen patients with FA cardiomyopathy (mean [SD] age, 25 [6] years; 11 [65%] female) were followed up for a mean (SD) of 20 (8) months. There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved. Other adverse events were transient, nonserious, or not treatment related. In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%). After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients. Excluding the patient with myocarditis, posttherapy values of serum hs troponin I were lower by at least 10% in 15 patients and higher by at least 10% in 2 patients. Conclusions and Relevance Findings of this nonrandomized clinical trial suggest that intravenous administration of AAVrh.10hFXN was well tolerated and may be a potential treatment for FA cardiomyopathy, as evidenced by preliminary improvement in exploratory efficacy end points. Trial Registration ClinicalTrials.gov Identifiers: NCT05302271 and NCT05445323
Guillain-Barré syndrome following intracranial hemorrhage: a systematic review of case reports
Vallamchetla, Sai Krishna , Pasya, Sai Kumar Reddy , Gronseth, Gary, Davalos, Long, Gronseth, Gary

Mayo Clinic

Frontiers in Neurology | June 17, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fneur.2026.1789597 | PMID 42388706 Get It

Introduction Guillain-Barré syndrome (GBS) is an autoimmune polyradiculopathy linked to various triggers. Recently, several case reports described GBS development following intracranial hemorrhage (ICH), posing diagnostic and therapeutic challenges. Methods PubMed and EMBASE were searched from inception till February 2023 for case reports. Two reviewers independently screened the articles and extracted data using a standardized form. The extracted data were then analyzed narratively. Quality was assessed with the JBI Checklist for Case Reports. Results Twenty-three cases from 11 countries were identified (14 males, mean age of 60.1 years). Onset of GBS occurred after a median of 9 days (range 2–24) post-ICH, with intracerebral hemorrhage being the most common antecedent (39.1%), followed by subarachnoid (26.1%) and subdural hemorrhage (21.7%). Electrophysiology showed predominantly axonal variants, while CSF consistently demonstrated albuminocytologic dissociation with positive antiganglioside antibodies in five cases. The clinical course was severe, marked by rapid progression to nadir (median 2.5 days), profound functional impairment (average Hughes Functional Grading Scale: 4.57 ± 0.66), and a high rate of respiratory failure requiring mechanical ventilation (78.3%). Axonal variants were associated with higher rates of mechanical ventilation and poorer outcomes than demyelinating forms. Among the 21 patients who received immunomodulatory treatment, 3 (14.3%) showed complete recovery, 13 (61.9%) had partial recovery, 3 (14.3%) had a poor recovery, and 2(9.5%) died at last follow up. Conclusion GBS may complicate recovery after ICH and appears to present with an aggressive course, particularly in axonal variants. Clinicians should consider GBS when patients with ICH develop progressive, symmetrical weakness unexplained by the initial brain injury, as prompt initiation of immunotherapy may improve outcomes.
Survival Trends in Waldenström Macroglobulinemia and Comparison of Outcomes with the General US Population
Zanwar, Saurabh , Khan, Muhammad Azeem , Gaur, Gunjan , Abeykoon, Jithma P. , Gertz, Morie A. , Kumar, Shaji , King, Rebecca, Habermann, Thomas M. , Go, Ronald S. , Abdallah, Nadine , Thanarajasingam, Gita , Thompson, CM, Nowakowski, Grzegorz S. , Dasari, Surendra , Novak, Joseph, Warsame, R., Ansell, Stephen M. , Kapoor, Prashant , Go, Ronald S , Gertz, Morie A , Habermann, Thomas , Paludo, Jonas , Cook, Joselle , Buadi, Francis K. , Dispenzieri, Angela , Gonsalves, Wilson I. , Dingli, David , Muchtar, Eli , Greipp, Patricia T. , Novak, Joseph P. , Warsame, Rahma , Witzig, Thomas E. , Rajkumar, S. Vincent

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9904019/v1 Get It

Abstract Therapeutic options for Waldenström macroglobulinemia (WM) have expanded but improvements in overall-survival (OS) are difficult to interpret due to competing non–WM mortality. We conducted a large single-center retrospective study of 1,020 patients with WM to evaluate survival trends. Patients were stratified by era of active WM diagnosis using a two-era model (1996–2005 and post-2005) and a four-era model (pre-2001, 2001–2007, 2008–2013, and post-2013). OS did not differ significantly across eras in the overall cohort (p = 0.64 and p = 0.86 for the two- and four-era models). However, among patients aged < 65 years at the time of active WM diagnosis in the 2-era model, OS improved in the post-2006 era (median 18.8 vs 14.1 years, p = 0.018). Cause-specific-survival (CSS) improved across all eras, increasing from 15.6 years in 1996–2005 to 18.9 years post-2006 (p < 0.0001), and from 13.7 years pre-2001 to not reached in later periods in the four-era model (p < 0.0001). Competing-risk-analysis (CRA) demonstrated a reduction in WM-related mortality over time (p < 0.001). However, excess mortality persisted, with a standardized mortality ratio (SMR) of 2.79 (p < 0.001) among patients < 65 years compared with a matched U.S. population. Our findings highlight improvements in WM-specific survival, while gains in OS are observed in younger patients.
Guillain-Barré Syndrome Following Intracranial Hemorrhage: A Systematic Review of Case Reports (P1-9.009)
Pasya, Sai Kumar Reddy , Vallamchetla, Sai Krishna, Gronseth, Gary, Davalos, Long, Vallamchetla, Sai Krishna , Gronseth, Gary

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000213235 Get It

Exploring the Tripartite Connection Between miRNA, Major Depression and Multiple Sclerosis and Thereby Proposing Their Early Diagnosis and Possible Therapeutic Modalities (P10-19.005)
Pillai, Ashvath, Pasya, Sai Kumar Reddy , Bokka, Vivek, Parmar, Japjee, Tiwari, Megha, Prasad, Sai, Bora, Satya, Mohammed, Omer , Vijayanarasimhan, Venkateshwaran , Karmarkar, Sambuddha, Fathima, Nimrah, Parmar, Japjee, Prasad, Sai

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216185 Get It

Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin for Cerebral Venous Thrombosis: An Updated Systematic Review and Meta-analysis (P3-5.010)
Vedula, Apoorva, Pasya, Sai Kumar Reddy , Vallamchetla, Saikrishna , Pillai, Ashvath, Jaikrishnan, Aishwarya, Kalyanasundaram, Bala Vignesh , Mutyala, Sarika, Al-Sabbagh, Mohammed Qussay Ali, Gronseth, Gary, Vedula, Apoorva, Vallamchetla, Sai Krishna , Mutyala, Sarika, Al-Sabbagh, Mohammed Qussay , Gronseth, Gary

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216368 Get It

Mayo Clinic Neurosonology Hybrid Course: First Cohort Results (P4-15.001)
Khan, Muhib, Dumitrascu, Oana, Hrdlicka, Courtney, Kumar, Gyanendra, Huang, Josephine, Braksick, Sherri, Coon, Elizabeth, Kramer, Christopher, Williams, Jeff, Brown, Robert, Hrdlicka, Courtney M. , Braksick, Sherri A. , Kramer, Christopher

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215013 Get It

Dose–Response Relationships and Comparative Efficacy of Aldosterone Synthase Inhibitors in Resistant Hypertension: A Comprehensive Network Meta-Analysis and Meta-Regression
Mohamed, Kareem A., Elshabrawi, Mohamed Nasser , Albeyoumi, Hossam , Khalil, Mohamed, AlGhazawy, Ahmed , Eshac, Youssof, Akoum, Atef , Sattar, Y, Das, Ashesh , Rahouma, Mohammed , Kumar, Akshay , Mohammed, Hossam Albeyoumi , Kumar, Akshay , Khalil, Mohamed, Eshac, Youssof , Kamal, Ibrahim

Mayo Clinic

Journal of Clinical Medicine | June 10, 2026 | Volume: 15 | Issue: 12 | Pages: 4477

10.3390/jcm15124477 | PMID 42355645 Get It

Background: Resistant hypertension represents a significant clinical challenge, often driven by dysregulated aldosterone production. Aldosterone synthase inhibitors (ASIs) are a novel therapeutic class designed to directly suppress aldosterone biosynthesis. This study aimed to synthesize evidence regarding the comparative efficacy, optimal dosing, and dose–response relationships of three ASIs—baxdrostat, lorundrostat, and osilodrostat—for the treatment of resistant hypertension. Methods: A systematic review and network meta-analysis (NMA) were conducted following PRISMA 2020 guidelines. We searched PubMed, Web of Science, and CENTRAL for randomized controlled trials (RCTs) published up to 31 October 2025. The primary outcome was the mean change in systolic blood pressure (SBP) compared to placebo. We utilized a frequentist random-effects model, characterized dose–response relationships via meta-regression, and ranked treatments using the Surface Under the Cumulative Ranking Curve (SUCRA). Results: The analysis included 8 RCTs comprising 3253 participants. Baxdrostat 2 mg once daily demonstrated the greatest antihypertensive efficacy with a mean SBP reduction of −13.8 mmHg (95% CI: −17.5 to −10.1) versus placebo, followed by Lorundrostat 100 mg (−12.5 mmHg) and Baxdrostat 1 mg (−11.5 mmHg). SUCRA analysis identified Baxdrostat as the highest-ranked treatment (83.0%), followed by Lorundrostat (67.8%) and Osilodrostat (55.5%). Dose–response meta-regression revealed strong linear correlations for Baxdrostat (R2 = 0.91), Osilodrostat (R2 = 0.81), and Lorundrostat (R2 = 0.80). Conclusions: ASIs, particularly Baxdrostat and Lorundrostat, offer robust blood pressure reductions in patients with resistant hypertension. The strong linear dose–response relationships suggest these agents have a favorable therapeutic window for titration. While effective, clinical implementation requires careful monitoring for adverse events.